A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2–10 ng/mL at initial biopsy

Molecular Cancer - Tập 20 - Trang 1-6 - 2021
Ya-Di He1, Wen Tao2, Tao He2, Bang-Yu Wang3, Xiu-Mei Tang1, Liang-Ming Zhang4, Zhen-Quan Wu5, Wei-Ming Deng6, Ling-Xiao Zhang7, Chun-Kui Shao8, Jing Zhou8, Li-Min Rong4, Xin Gao2, Liao-Yuan Li2
1Centre of Physical Examination, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
2Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3Breast Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
4Department of Spine Surgery, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
5Department of Urology, Foshan First Municipal People’s Hospital, Sun Yat-Sen University, Foshan, China
6Department of Urology, The First Affiliated Hospital, University of South China, Hengyang, China
7Department of Urology, The First Affiliated Hospital, Hainan Medical College, Haikou, China
8Department of Pathology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

Tóm tắt

The aim of this study was to identify a urine extracellular vesicle circular RNA (circRNA) classifier that could detect high-grade prostate cancer (PCa) of Grade Group (GG) 2 or greater. For this purpose, we used RNA sequencing to identify candidate circRNAs from urinary extracellular vesicles from 11 patients with high-grade PCa and 11 case-matched patients with benign prostatic hyperplasia. Using ddPCR in a training cohort (n = 263), we built a urine extracellular vesicle circRNA classifier (Ccirc, containing circPDLIM5, circSCAF8, circPLXDC2, circSCAMP1, and circCCNT2), which was evaluated in two independent cohorts (n = 497, n = 505). Ccirc showed higher accuracy than two standard of care risk calculators (RCs) (PCPT-RC 2.0 and ERSPC-RC) in both the training cohort and the validation cohorts. In all three cohorts, this novel urine extracellular vesicle circRNA classifier plus RCs was statistically more predictive than RCs alone for predicting ≥ GG2 PCa. This assay, which does not require precollection digital rectal examination nor special handling, is repeatable, noninvasive, and can be easily implemented as part of the basic clinical workflow.

Tài liệu tham khảo

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48(3):386–99. Xu T, Lin CM, Cheng SQ, et al. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star. Mol Cancer. 2018;17(1):103. Chen S, Huang V, Xu X, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 2019;176(4):831-43.e22. Wang Y, Liu J, Ma J, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019;18(1):116. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362–7. Foley RW, Maweni RM, Gorman L, et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118(5):706–13. Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2017;41(4):e1–7. Vo JN, Cieslik M, Zhang Y, et al. The Landscape of Circular RNA in Cancer. Cell. 2019;176(4):869-81.e813. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. 2016;70(1):45–53. Cucchiara V, Cooperberg MR, Dall’Era M, et al. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018;73(4):572–82. Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012;13(11):e509–17.